BRAF and cutaneous melanoma: In another recent large clinical study by Mahrukh et al. [78], ctDNA BRAF V600E SNV was analyzed in 383 baseline and 262 on-treatment plasma samples for patients enrolled in COMBI-d [79] and COMBI-MB [80] studies using droplet digital PCR assays to evaluate whether ctDNA could predict survival outcomes for advanced cutaneous melanoma patients treated with dabrafenib or dabrafenib plus trametinib.